Synthesis and immunological activity of water-soluble Thalidomide prodrugs
A series of new water-soluble thalidomide prodrugs was prepared. All compounds were derivatized on the nitrogen of the glutarimide ring. Esters of natural amino acids and succinic acid derivatives have been introduced by reaction with the hydroxymethyl thalidomide 2. Nicotinic acid derivatives were...
Gespeichert in:
Veröffentlicht in: | Bioorganic & medicinal chemistry 2001-05, Vol.9 (5), p.1279-1291 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1291 |
---|---|
container_issue | 5 |
container_start_page | 1279 |
container_title | Bioorganic & medicinal chemistry |
container_volume | 9 |
creator | Hess, Sonja Akermann, Michaela A. Wnendt, Stephan Zwingenberger, Kai Eger, Kurt |
description | A series of new water-soluble thalidomide prodrugs was prepared. All compounds were derivatized on the nitrogen of the glutarimide ring. Esters of natural amino acids and succinic acid derivatives have been introduced by reaction with the hydroxymethyl thalidomide
2. Nicotinic acid derivatives were prepared from halomethyl derivatives. Additionally, a methoxymethyl derivative and a carboxymethyl derivative were prepared directly from thalidomide. Most compounds showed a very large increase in water solubility compared to thalidomide itself (0.012
mg/mL). The amorphous hydrochlorides of the
N-methylalanine ester
8, valine ester
9, and glycylglycine ester
10, respectively, were the most soluble compounds showing solubility greater than 300
mg/mL, which equals an increase greater than 15,000-fold. The lipophilicity of the prodrugs has been determined by their HPLC capacity factors
k′. The stability of selected compounds was determined. The hydrolysis rates follow pseudo-first order kinetics. In order to assess the immunological activity, the prodrugs were tested using tumor necrosis factor-α and interleukin-2 inhibition assays. Selected compounds were additionally investigated on their abililty to inhibit the local Shwartzman reaction, an assay to determine the vascular permeability. The prodrugs retained high effectiveness in the inhibition of TNF-α release. Our results indicated that the more stable prodrugs exhibited higher activity in the immunological assays. Some compounds showed higher activity than thalidomide itself, suggesting a high affine binding to the pharmacophore. In conclusion, the prodrugs exhibited high water solubility and high activity and might therefore be used in therapeutic applications.
Graphic |
doi_str_mv | 10.1016/S0968-0896(00)00342-4 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70880694</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0968089600003424</els_id><sourcerecordid>70880694</sourcerecordid><originalsourceid>FETCH-LOGICAL-c480t-5cf1dcfba28ac82afd235c87de03e2854ec22727cf282a29a9f7bb3c4b4f9b293</originalsourceid><addsrcrecordid>eNqFkE1P3DAQhi0EKtttfwJVJCTUHgLjj03sE0KrfoCQOOz2bDn2GFwlMdgJ1f57suwKjpzmMM877-gh5ITCOQVaXaxAVbIEqarvAD8AuGClOCAzKipRcq7oIZm9Icfkc87_AIAJRT-RY0p5XVNZzcjNatMPD5hDLkzvitB1Yx_beB-saQtjh_Achk0RffHfDJjKHNuxabFYP5g2uNgFh8Vjii6N9_kLOfKmzfh1P-fk76-f6-Wf8vbu9_Xy6ra0QsJQLqynzvrGMGmsZMY7xhdW1g6BI5MLgZaxmtXWs2nLlFG-bhpuRSO8apjic3K2uzsVP42YB92FbLFtTY9xzLoGKaFSYgIXO9CmmHNCrx9T6EzaaAp6K1G_StRbQxpAv0rU29y3fcHYdOjeU3trE3C6B0yePPlkehvyG6dUzSSfqMsdhZOM54BJZxuwt-hCQjtoF8MHj7wAt6KPcA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70880694</pqid></control><display><type>article</type><title>Synthesis and immunological activity of water-soluble Thalidomide prodrugs</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Hess, Sonja ; Akermann, Michaela A. ; Wnendt, Stephan ; Zwingenberger, Kai ; Eger, Kurt</creator><creatorcontrib>Hess, Sonja ; Akermann, Michaela A. ; Wnendt, Stephan ; Zwingenberger, Kai ; Eger, Kurt</creatorcontrib><description>A series of new water-soluble thalidomide prodrugs was prepared. All compounds were derivatized on the nitrogen of the glutarimide ring. Esters of natural amino acids and succinic acid derivatives have been introduced by reaction with the hydroxymethyl thalidomide
2. Nicotinic acid derivatives were prepared from halomethyl derivatives. Additionally, a methoxymethyl derivative and a carboxymethyl derivative were prepared directly from thalidomide. Most compounds showed a very large increase in water solubility compared to thalidomide itself (0.012
mg/mL). The amorphous hydrochlorides of the
N-methylalanine ester
8, valine ester
9, and glycylglycine ester
10, respectively, were the most soluble compounds showing solubility greater than 300
mg/mL, which equals an increase greater than 15,000-fold. The lipophilicity of the prodrugs has been determined by their HPLC capacity factors
k′. The stability of selected compounds was determined. The hydrolysis rates follow pseudo-first order kinetics. In order to assess the immunological activity, the prodrugs were tested using tumor necrosis factor-α and interleukin-2 inhibition assays. Selected compounds were additionally investigated on their abililty to inhibit the local Shwartzman reaction, an assay to determine the vascular permeability. The prodrugs retained high effectiveness in the inhibition of TNF-α release. Our results indicated that the more stable prodrugs exhibited higher activity in the immunological assays. Some compounds showed higher activity than thalidomide itself, suggesting a high affine binding to the pharmacophore. In conclusion, the prodrugs exhibited high water solubility and high activity and might therefore be used in therapeutic applications.
Graphic</description><identifier>ISSN: 0968-0896</identifier><identifier>EISSN: 1464-3391</identifier><identifier>DOI: 10.1016/S0968-0896(00)00342-4</identifier><identifier>PMID: 11377186</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject>Animals ; Binding Sites ; Biological and medical sciences ; Drug Stability ; Humans ; Hydrogen-Ion Concentration ; Hydrolysis ; Immunomodulators ; Interleukin-2 - antagonists & inhibitors ; Interleukin-2 - biosynthesis ; Kinetics ; Male ; Medical sciences ; Mice ; Permeability ; Pharmacology. Drug treatments ; Shwartzman Phenomenon - metabolism ; Solubility ; Thalidomide - chemical synthesis ; Thalidomide - chemistry ; Thalidomide - pharmacology ; Tumor Necrosis Factor-alpha - antagonists & inhibitors ; Water - chemistry</subject><ispartof>Bioorganic & medicinal chemistry, 2001-05, Vol.9 (5), p.1279-1291</ispartof><rights>2001 Elsevier Science Ltd</rights><rights>2001 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c480t-5cf1dcfba28ac82afd235c87de03e2854ec22727cf282a29a9f7bb3c4b4f9b293</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/S0968-0896(00)00342-4$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,778,782,3539,27907,27908,45978</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=997283$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11377186$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hess, Sonja</creatorcontrib><creatorcontrib>Akermann, Michaela A.</creatorcontrib><creatorcontrib>Wnendt, Stephan</creatorcontrib><creatorcontrib>Zwingenberger, Kai</creatorcontrib><creatorcontrib>Eger, Kurt</creatorcontrib><title>Synthesis and immunological activity of water-soluble Thalidomide prodrugs</title><title>Bioorganic & medicinal chemistry</title><addtitle>Bioorg Med Chem</addtitle><description>A series of new water-soluble thalidomide prodrugs was prepared. All compounds were derivatized on the nitrogen of the glutarimide ring. Esters of natural amino acids and succinic acid derivatives have been introduced by reaction with the hydroxymethyl thalidomide
2. Nicotinic acid derivatives were prepared from halomethyl derivatives. Additionally, a methoxymethyl derivative and a carboxymethyl derivative were prepared directly from thalidomide. Most compounds showed a very large increase in water solubility compared to thalidomide itself (0.012
mg/mL). The amorphous hydrochlorides of the
N-methylalanine ester
8, valine ester
9, and glycylglycine ester
10, respectively, were the most soluble compounds showing solubility greater than 300
mg/mL, which equals an increase greater than 15,000-fold. The lipophilicity of the prodrugs has been determined by their HPLC capacity factors
k′. The stability of selected compounds was determined. The hydrolysis rates follow pseudo-first order kinetics. In order to assess the immunological activity, the prodrugs were tested using tumor necrosis factor-α and interleukin-2 inhibition assays. Selected compounds were additionally investigated on their abililty to inhibit the local Shwartzman reaction, an assay to determine the vascular permeability. The prodrugs retained high effectiveness in the inhibition of TNF-α release. Our results indicated that the more stable prodrugs exhibited higher activity in the immunological assays. Some compounds showed higher activity than thalidomide itself, suggesting a high affine binding to the pharmacophore. In conclusion, the prodrugs exhibited high water solubility and high activity and might therefore be used in therapeutic applications.
Graphic</description><subject>Animals</subject><subject>Binding Sites</subject><subject>Biological and medical sciences</subject><subject>Drug Stability</subject><subject>Humans</subject><subject>Hydrogen-Ion Concentration</subject><subject>Hydrolysis</subject><subject>Immunomodulators</subject><subject>Interleukin-2 - antagonists & inhibitors</subject><subject>Interleukin-2 - biosynthesis</subject><subject>Kinetics</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Permeability</subject><subject>Pharmacology. Drug treatments</subject><subject>Shwartzman Phenomenon - metabolism</subject><subject>Solubility</subject><subject>Thalidomide - chemical synthesis</subject><subject>Thalidomide - chemistry</subject><subject>Thalidomide - pharmacology</subject><subject>Tumor Necrosis Factor-alpha - antagonists & inhibitors</subject><subject>Water - chemistry</subject><issn>0968-0896</issn><issn>1464-3391</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE1P3DAQhi0EKtttfwJVJCTUHgLjj03sE0KrfoCQOOz2bDn2GFwlMdgJ1f57suwKjpzmMM877-gh5ITCOQVaXaxAVbIEqarvAD8AuGClOCAzKipRcq7oIZm9Icfkc87_AIAJRT-RY0p5XVNZzcjNatMPD5hDLkzvitB1Yx_beB-saQtjh_Achk0RffHfDJjKHNuxabFYP5g2uNgFh8Vjii6N9_kLOfKmzfh1P-fk76-f6-Wf8vbu9_Xy6ra0QsJQLqynzvrGMGmsZMY7xhdW1g6BI5MLgZaxmtXWs2nLlFG-bhpuRSO8apjic3K2uzsVP42YB92FbLFtTY9xzLoGKaFSYgIXO9CmmHNCrx9T6EzaaAp6K1G_StRbQxpAv0rU29y3fcHYdOjeU3trE3C6B0yePPlkehvyG6dUzSSfqMsdhZOM54BJZxuwt-hCQjtoF8MHj7wAt6KPcA</recordid><startdate>20010501</startdate><enddate>20010501</enddate><creator>Hess, Sonja</creator><creator>Akermann, Michaela A.</creator><creator>Wnendt, Stephan</creator><creator>Zwingenberger, Kai</creator><creator>Eger, Kurt</creator><general>Elsevier Ltd</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20010501</creationdate><title>Synthesis and immunological activity of water-soluble Thalidomide prodrugs</title><author>Hess, Sonja ; Akermann, Michaela A. ; Wnendt, Stephan ; Zwingenberger, Kai ; Eger, Kurt</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c480t-5cf1dcfba28ac82afd235c87de03e2854ec22727cf282a29a9f7bb3c4b4f9b293</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Animals</topic><topic>Binding Sites</topic><topic>Biological and medical sciences</topic><topic>Drug Stability</topic><topic>Humans</topic><topic>Hydrogen-Ion Concentration</topic><topic>Hydrolysis</topic><topic>Immunomodulators</topic><topic>Interleukin-2 - antagonists & inhibitors</topic><topic>Interleukin-2 - biosynthesis</topic><topic>Kinetics</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Permeability</topic><topic>Pharmacology. Drug treatments</topic><topic>Shwartzman Phenomenon - metabolism</topic><topic>Solubility</topic><topic>Thalidomide - chemical synthesis</topic><topic>Thalidomide - chemistry</topic><topic>Thalidomide - pharmacology</topic><topic>Tumor Necrosis Factor-alpha - antagonists & inhibitors</topic><topic>Water - chemistry</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hess, Sonja</creatorcontrib><creatorcontrib>Akermann, Michaela A.</creatorcontrib><creatorcontrib>Wnendt, Stephan</creatorcontrib><creatorcontrib>Zwingenberger, Kai</creatorcontrib><creatorcontrib>Eger, Kurt</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Bioorganic & medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hess, Sonja</au><au>Akermann, Michaela A.</au><au>Wnendt, Stephan</au><au>Zwingenberger, Kai</au><au>Eger, Kurt</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Synthesis and immunological activity of water-soluble Thalidomide prodrugs</atitle><jtitle>Bioorganic & medicinal chemistry</jtitle><addtitle>Bioorg Med Chem</addtitle><date>2001-05-01</date><risdate>2001</risdate><volume>9</volume><issue>5</issue><spage>1279</spage><epage>1291</epage><pages>1279-1291</pages><issn>0968-0896</issn><eissn>1464-3391</eissn><abstract>A series of new water-soluble thalidomide prodrugs was prepared. All compounds were derivatized on the nitrogen of the glutarimide ring. Esters of natural amino acids and succinic acid derivatives have been introduced by reaction with the hydroxymethyl thalidomide
2. Nicotinic acid derivatives were prepared from halomethyl derivatives. Additionally, a methoxymethyl derivative and a carboxymethyl derivative were prepared directly from thalidomide. Most compounds showed a very large increase in water solubility compared to thalidomide itself (0.012
mg/mL). The amorphous hydrochlorides of the
N-methylalanine ester
8, valine ester
9, and glycylglycine ester
10, respectively, were the most soluble compounds showing solubility greater than 300
mg/mL, which equals an increase greater than 15,000-fold. The lipophilicity of the prodrugs has been determined by their HPLC capacity factors
k′. The stability of selected compounds was determined. The hydrolysis rates follow pseudo-first order kinetics. In order to assess the immunological activity, the prodrugs were tested using tumor necrosis factor-α and interleukin-2 inhibition assays. Selected compounds were additionally investigated on their abililty to inhibit the local Shwartzman reaction, an assay to determine the vascular permeability. The prodrugs retained high effectiveness in the inhibition of TNF-α release. Our results indicated that the more stable prodrugs exhibited higher activity in the immunological assays. Some compounds showed higher activity than thalidomide itself, suggesting a high affine binding to the pharmacophore. In conclusion, the prodrugs exhibited high water solubility and high activity and might therefore be used in therapeutic applications.
Graphic</abstract><cop>Oxford</cop><pub>Elsevier Ltd</pub><pmid>11377186</pmid><doi>10.1016/S0968-0896(00)00342-4</doi><tpages>13</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0968-0896 |
ispartof | Bioorganic & medicinal chemistry, 2001-05, Vol.9 (5), p.1279-1291 |
issn | 0968-0896 1464-3391 |
language | eng |
recordid | cdi_proquest_miscellaneous_70880694 |
source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
subjects | Animals Binding Sites Biological and medical sciences Drug Stability Humans Hydrogen-Ion Concentration Hydrolysis Immunomodulators Interleukin-2 - antagonists & inhibitors Interleukin-2 - biosynthesis Kinetics Male Medical sciences Mice Permeability Pharmacology. Drug treatments Shwartzman Phenomenon - metabolism Solubility Thalidomide - chemical synthesis Thalidomide - chemistry Thalidomide - pharmacology Tumor Necrosis Factor-alpha - antagonists & inhibitors Water - chemistry |
title | Synthesis and immunological activity of water-soluble Thalidomide prodrugs |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T13%3A54%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Synthesis%20and%20immunological%20activity%20of%20water-soluble%20Thalidomide%20prodrugs&rft.jtitle=Bioorganic%20&%20medicinal%20chemistry&rft.au=Hess,%20Sonja&rft.date=2001-05-01&rft.volume=9&rft.issue=5&rft.spage=1279&rft.epage=1291&rft.pages=1279-1291&rft.issn=0968-0896&rft.eissn=1464-3391&rft_id=info:doi/10.1016/S0968-0896(00)00342-4&rft_dat=%3Cproquest_cross%3E70880694%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=70880694&rft_id=info:pmid/11377186&rft_els_id=S0968089600003424&rfr_iscdi=true |